One of the most fun events at every annual meeting is the ACR Knowledge Bowl. In this quiz show-style trivia game, fellows form teams to compete for top prizes. There’s a charismatic host, a panel of esteemed judges and an auditorium packed with cheering spectators. Beyond the fun of competing against your peers from other…
The ACR Education Exchange 2023 session titled Updates from the Committee on Rheumatology Training & Workforce Issues provided information on fellows-in-training scholarships, Rheumatology Research Foundation awards & more.
Speakers addressed major challenges in coverage and payment facing rheumatology practices, including financial management and obstacles to patient access to treatment.
Disparities, representativeness, algorithmic bias, the disruptive emergence of large language models and continued misinformation spread are key issues poised to transform patient care in American healthcare, FDA Commissioner Robert M. Califf, MD, said during a recent event.
Patient advocates, researcher-clinicians and academic leaders are calling for closer scrutiny of new technologies applied within healthcare, citing concerns about a lack of consideration for how they may affect patient care.
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
This program offers loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a three-year, full-time service commitment at an approved facility in an underserved area. Pediatric rheumatologists are encouraged to apply.
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.
New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.